Facebook
Twitter
LinkedIn
ForwardInnovative Trials in Systemic Therapy, Radiation and Surgery in Head and Neck Cancers
This activity seeks to review innovative clinical trials in the treatment of head and neck cancers from a radiation, surgical and systemic therapy perspective. These trials have novel translational components that may spearhead the next generation of novel clinical trials in these diseases. Further, this session will also provide information regarding the FDA’s Project Optimus which seeks to optimize dose delivery and duration of cancer therapeutics which will also be critical in the setting of novel clinical trials.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Describe changes related to neoadjuvant radiotherapy for head and neck squamous cancers.
- Describe changes related to neoadjuvant immunotherapeutics for head and neck squamous cancers.
- Understanding viral targeting as a systemic therapeutic approach for HPV-relate cancers.
Musaddiq Awan, MD, is employed by the Medical College of Wisconsin and receives research compensation from Genentech and NIH. He holds leadership positions with NRG Oncology.
Nancy Lee, MD, FASTRO, is employed by Memorial Sloan Kettering Cancer Center and has no financial relationships with a commercial interest.
Stuart Wong, MD, is employed by the Medical College of Wisconsin and has no financial relationships with a commercial interest.
Clint Allen, MD, is employed by the National Institutes of Health and has no financial relationships with a commercial interest.
Joseph Zenga, MD, is employed by the Medical College of Wisconsin and has no financial relationships with a commercial interest.
Stacy Shord, PharmD, is employed by the FDA and has no financial relationships with a commercial interest.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.